The DPYSL3 (Dihydropyrimidinase-like 3) gene, also known as CRMP3 (Collapsin Response Mediator Protein 3), encodes a cytosolic phosphoprotein belonging to the DPYSL/CRMP family. These proteins are critically involved in neuronal development, including axon guidance, dendritic patterning, and synaptic plasticity, primarily through interactions with tubulin heterodimers and microtubule dynamics. DPYSL3 is expressed in the nervous system and other tissues, playing roles in signal transduction and cytoskeletal reorganization.
Antibodies targeting DPYSL3 are widely used in research to investigate its expression, localization, and function in physiological and pathological contexts. For example, studies employ DPYSL3 antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore its role in neurodegenerative diseases (e.g., Alzheimer’s), neurodevelopmental disorders, and cancer. In oncology, DPYSL3 has been implicated in tumor progression and metastasis, with altered expression observed in malignancies such as breast cancer and glioblastoma.
Commercially available DPYSL3 antibodies are typically validated for specificity and application compatibility. However, researchers must verify cross-reactivity due to homology among DPYSL family members. Understanding DPYSL3's molecular interactions and pathways through antibody-based assays contributes to elucidating its therapeutic potential, particularly in modulating cytoskeletal dynamics or signaling cascades in disease models.